Replies to post #1155 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>what do you think the odds are that NM283 goes to P3?<

I’ll stick with the 61% probability mentioned in #msg-19911721 for a successful drug-interaction study, which will by definition advance NM283 into phase-3.

If the drug-interaction study is unsuccessful, there is some residual chance that NM283 gets to phase-3 as a replacement for ribavirin in some yet unspecified patient group. I’ll add another 6% for this vig, which brings the probability of advancing to phase-3 up to 67%. JMHO, FWIW